Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Sept 2023

Sanchez-Martin Anabel, Sanchon-Sanchez Paula, Romero Marta R, Marin Jose J G, Briz Oscar

Abstract excerpt

The response of advanced hepatocellular carcinoma (HCC) to pharmacological treatments is unsatisfactory and heterogeneous. Inactivation of tumor suppressor genes (TSGs) by genetic and epigenetic events is frequent in HCC. This study aimed at investigating the impact of frequently altered TSGs on HCC chemoresistance. TSG alterations were screened by in silico analysis of TCGA-LIHC database, and their relationship...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Doxorubicin

Share to Drug Resistance, Multiple

Share to Genes, Tumor Suppressor

Share to Liver Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 37499450
DOI: 10.1016/j.biopha.2023.115209

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells.PMID 37499450Read ↗

Clinical value of identifying genes that inhibit hepatocellular carcinomas.Semantic proximity Read ↗

Mechanisms of drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

Systematic decoding of the resistance mechanisms and therapeutic vulnerabilities in TKI-resistant hepatocellular carcinomaSemantic proximity Read ↗

Drug Resistance in Hepatocellular Carcinoma: Theoretical Basis and Therapeutic AspectsSemantic proximity Read ↗

Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinomaSemantic proximity Read ↗

Chemoresistance and genetic mutations in hepatocellular carcinoma: a pharmacogenomic atlas of 51 patients.Semantic proximity Read ↗

Molecular perspectives for the treatment of hepatocellular carcinoma.Semantic proximity Read ↗

Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinomaSemantic proximity Read ↗

Coordinated activation of DNMT3a and TET2 in cancer stem cell-like cells initiates and sustains drug resistance in hepatocellular carcinomaSemantic proximity Read ↗

Loss of cBAF Complex Confers Sorafenib Resistance in Liver CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.